PPARG and asthma: For instance, Richards et al. conducted a single-center, double-blind, randomized, placebo-controlled, two-period crossover study exploring the effects of rosiglitazone, which is a PPARγ agonist, on the late asthmatic reaction in an allergen challenge model of asthma [158].